Analysis of the TCGA RNA-seq data further showed that TIGIT and NECTIN2 high expression was correlated with more progressive disease across 14 cancer types, including HCC (Fig. 7e; Supplementary Table S7), suggesting targeting TIGIT‒NECTIN2 to inhibit stromal‒immune interactions may be a potent alternative to directly reduce CAF-FAP to fuel ICB response. The gene discussed is NECTIN2; the disease is cancer.